HU224028B1 - Fumagillol és származékai alkalmazása bélfertőzések kezelésére szolgáló gyógyszerek előállítására - Google Patents
Fumagillol és származékai alkalmazása bélfertőzések kezelésére szolgáló gyógyszerek előállítására Download PDFInfo
- Publication number
- HU224028B1 HU224028B1 HU9801220A HUP9801220A HU224028B1 HU 224028 B1 HU224028 B1 HU 224028B1 HU 9801220 A HU9801220 A HU 9801220A HU P9801220 A HUP9801220 A HU P9801220A HU 224028 B1 HU224028 B1 HU 224028B1
- Authority
- HU
- Hungary
- Prior art keywords
- fumagillol
- ester
- active ingredient
- pharmaceutical composition
- patients
- Prior art date
Links
- CEVCTNCUIVEQOY-UHFFFAOYSA-N Fumagillol Natural products O1C(CC=C(C)C)C1(C)C1C(OC)C(O)CCC21CO2 CEVCTNCUIVEQOY-UHFFFAOYSA-N 0.000 title claims abstract description 24
- CEVCTNCUIVEQOY-STXHBLNNSA-N fumagillol Chemical compound C([C@@H](O)[C@H](C1[C@]2(C)[C@H](O2)CC=C(C)C)OC)C[C@@]21CO2 CEVCTNCUIVEQOY-STXHBLNNSA-N 0.000 title claims abstract description 24
- 239000003814 drug Substances 0.000 title claims abstract description 11
- 206010022678 Intestinal infections Diseases 0.000 title claims abstract description 9
- -1 alkyl dicarboxylic acids Chemical class 0.000 claims abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 15
- 229920006395 saturated elastomer Polymers 0.000 claims abstract description 9
- 239000004480 active ingredient Substances 0.000 claims description 16
- 150000002148 esters Chemical class 0.000 claims description 15
- 241000243190 Microsporidia Species 0.000 claims description 12
- NGGMYCMLYOUNGM-UHFFFAOYSA-N (-)-fumagillin Natural products O1C(CC=C(C)C)C1(C)C1C(OC)C(OC(=O)C=CC=CC=CC=CC(O)=O)CCC21CO2 NGGMYCMLYOUNGM-UHFFFAOYSA-N 0.000 claims description 10
- NGGMYCMLYOUNGM-CSDLUJIJSA-N fumagillin Chemical group C([C@H]([C@H]([C@@H]1[C@]2(C)[C@H](O2)CC=C(C)C)OC)OC(=O)\C=C\C=C\C=C\C=C\C(O)=O)C[C@@]21CO2 NGGMYCMLYOUNGM-CSDLUJIJSA-N 0.000 claims description 10
- 229960000936 fumagillin Drugs 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 7
- 241001126836 Enterocytozoon Species 0.000 claims description 6
- 244000045947 parasite Species 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- 238000013270 controlled release Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims 2
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 239000002253 acid Substances 0.000 abstract description 9
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 241000223935 Cryptosporidium Species 0.000 abstract description 2
- 241001295810 Microsporidium Species 0.000 abstract description 2
- 150000007513 acids Chemical class 0.000 abstract description 2
- 208000015181 infectious disease Diseases 0.000 description 6
- 239000000203 mixture Substances 0.000 description 5
- 208000030507 AIDS Diseases 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 230000002183 duodenal effect Effects 0.000 description 3
- 230000008029 eradication Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000003108 parasitologic effect Effects 0.000 description 3
- 206010001513 AIDS related complex Diseases 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- QKDJUYZFQZUBNY-UHFFFAOYSA-N CC=CC=CC=CC=CC(C(=O)O)C(=O)O Chemical compound CC=CC=CC=CC=CC(C(=O)O)C(=O)O QKDJUYZFQZUBNY-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000003096 antiparasitic agent Substances 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- LDHQCZJRKDOVOX-UHFFFAOYSA-N trans-crotonic acid Natural products CC=CC(O)=O LDHQCZJRKDOVOX-UHFFFAOYSA-N 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 241000220479 Acacia Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 208000008953 Cryptosporidiosis Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241001126846 Encephalitozoon hellem Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 206010059440 Platelet toxicity Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940125687 antiparasitic agent Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000003167 cholangitis Diseases 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- LDHQCZJRKDOVOX-NSCUHMNNSA-N crotonic acid Chemical compound C\C=C\C(O)=O LDHQCZJRKDOVOX-NSCUHMNNSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000000652 homosexual effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- LDHQCZJRKDOVOX-IHWYPQMZSA-N isocrotonic acid Chemical compound C\C=C/C(O)=O LDHQCZJRKDOVOX-IHWYPQMZSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 238000009372 pisciculture Methods 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 231100000201 platelet toxicity Toxicity 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epoxy Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9503549 | 1995-03-27 | ||
| PCT/FR1996/000448 WO1996030010A2 (fr) | 1995-03-27 | 1996-03-26 | Utilisation du fumagillol et ses derives pour preparer les medicaments destines a combattre les infections intestinales |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| HUP9801220A2 HUP9801220A2 (hu) | 1999-09-28 |
| HUP9801220A3 HUP9801220A3 (en) | 2001-10-29 |
| HU224028B1 true HU224028B1 (hu) | 2005-05-30 |
Family
ID=9477436
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU9801220A HU224028B1 (hu) | 1995-03-27 | 1996-03-26 | Fumagillol és származékai alkalmazása bélfertőzések kezelésére szolgáló gyógyszerek előállítására |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US5900431A (enExample) |
| EP (1) | EP0817626B1 (enExample) |
| JP (1) | JP3260378B2 (enExample) |
| KR (1) | KR100286920B1 (enExample) |
| CN (1) | CN1072485C (enExample) |
| AP (1) | AP646A (enExample) |
| AT (1) | ATE172641T1 (enExample) |
| AU (1) | AU706161B2 (enExample) |
| CA (1) | CA2216623C (enExample) |
| CZ (1) | CZ286821B6 (enExample) |
| DE (1) | DE69600879T2 (enExample) |
| DK (1) | DK0817626T3 (enExample) |
| EA (1) | EA000150B1 (enExample) |
| ES (1) | ES2128846T3 (enExample) |
| FR (1) | FR06C0014I2 (enExample) |
| HU (1) | HU224028B1 (enExample) |
| IS (1) | IS2048B (enExample) |
| NO (1) | NO315968B1 (enExample) |
| NZ (1) | NZ304906A (enExample) |
| OA (1) | OA10515A (enExample) |
| PL (1) | PL183378B1 (enExample) |
| SK (1) | SK283883B6 (enExample) |
| TR (1) | TR199701048T1 (enExample) |
| UA (1) | UA41446C2 (enExample) |
| WO (1) | WO1996030010A2 (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2216623C (en) * | 1995-03-27 | 2005-05-31 | Sanofi | Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections |
| EP0799616A1 (en) * | 1996-04-01 | 1997-10-08 | Takeda Chemical Industries, Ltd. | Oral composition comprising a fumagillol derivative |
| WO2000050084A1 (fr) * | 1999-02-26 | 2000-08-31 | Sanofi-Synthelabo | Formulation stable contenant de la fumagilline |
| JP3265394B1 (ja) * | 2001-03-14 | 2002-03-11 | 泰三 矢野 | アクリル系樹脂手袋 |
| DE10341887A1 (de) * | 2003-09-09 | 2005-03-31 | Leopold Kostal Gmbh & Co. Kg | Elektrisches Schaltermodul |
| FR2886855B1 (fr) * | 2005-06-08 | 2009-07-17 | Agronomique Inst Nat Rech | Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques |
| CA2706914A1 (en) * | 2007-11-28 | 2009-06-11 | Mersana Therapeutics, Inc. | Biocompatible biodegradable fumagillin analog conjugates |
| CA2731020A1 (en) * | 2008-07-18 | 2010-01-21 | Zafgen, Inc. | Use of antiangiogenic fumagillins in the treatment of obesity |
| WO2010065877A2 (en) | 2008-12-04 | 2010-06-10 | Zafgen Corporation | Methods of treating an overweight or obese subject |
| WO2010065883A2 (en) | 2008-12-04 | 2010-06-10 | Zafgen Corporation | Method of treating an overweight or obese subject |
| WO2013055385A2 (en) | 2011-10-03 | 2013-04-18 | Zafgen Corporation | Methods of treating age related disorders |
| EP2486004B1 (en) | 2009-10-09 | 2017-05-03 | Zafgen, Inc. | Sulphone compounds for use in the treatment of obesity |
| EP2521719B1 (en) | 2010-01-08 | 2015-07-29 | Zafgen, Inc. | Fumagillol type compounds and methods of making and using same |
| WO2011085198A1 (en) | 2010-01-08 | 2011-07-14 | Zafgen Corporation | Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph) |
| WO2011127304A2 (en) | 2010-04-07 | 2011-10-13 | Zafgen Corporation | Methods of treating an overweight subject |
| CA2806221A1 (en) | 2010-07-22 | 2012-01-26 | Zafgen, Inc. | Tricyclic compounds and methods of making and using same |
| PH12013500934A1 (en) | 2010-11-09 | 2022-10-24 | Zafgen Inc | Crystalline solids of a metap-2 inhibitor and methods of making and using same |
| JP2013543899A (ja) | 2010-11-29 | 2013-12-09 | ザフゲン，インコーポレイテッド | ６−ｏ−（４−ジメチルアミノエトキシ）シンナモイルフマギロールの非連日投与を用いた肥満の治療 |
| EP2668169B1 (en) | 2011-01-26 | 2017-11-15 | Zafgen, Inc. | Tetrazole compounds and methods of making and using same |
| CN103534244B (zh) | 2011-03-08 | 2016-10-12 | 扎夫根股份有限公司 | 氧杂螺[2.5]辛烷衍生物及类似物 |
| MX343687B (es) | 2011-05-06 | 2016-11-16 | Zafgen Inc | Compuestos sulfonamida tricíclica y métodos para su fabricación y uso. |
| BR112013028666A2 (pt) | 2011-05-06 | 2017-08-08 | Zafgen Inc | compostos de pirazolo sulfonamida tricícilos e métodos para fazer e usar o mesmo |
| EP2705030B1 (en) | 2011-05-06 | 2016-07-27 | Zafgen, Inc. | Partially saturated tricyclic compounds and methods of making and using same |
| BR112014017673A8 (pt) | 2012-01-18 | 2017-07-11 | Zafgen Inc | Compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos |
| WO2013109735A1 (en) | 2012-01-18 | 2013-07-25 | Zafgen, Inc. | Tricyclic sulfone compounds and methods of making and using same |
| EP2847176A1 (en) | 2012-05-07 | 2015-03-18 | Zafgen, Inc. | Polymorphic salt of the oxalate salt of 6 - o - ( 4 - dimethylaminoethoxy) cinnarnoyl fumagillol and methods of making and using same |
| EP2846792B1 (en) | 2012-05-08 | 2018-08-15 | Zafgen, Inc. | Treating hypothalamic obesity with metap2 inhibitors |
| CA2873574A1 (en) | 2012-05-09 | 2013-11-14 | Zafgen, Inc. | Fumagillol type compounds and methods of making and using same |
| US9868717B2 (en) | 2012-11-05 | 2018-01-16 | Zafgen, Inc. | Tricyclic sulphonamide compounds and methods of making and using same |
| AU2013337287B2 (en) | 2012-11-05 | 2017-03-23 | Zafgen, Inc. | Methods of treating liver diseases |
| US10174009B2 (en) | 2012-11-05 | 2019-01-08 | Zafgen, Inc. | Tricyclic sulphonamide compounds and methods of making and using same |
| MX362391B (es) | 2013-03-14 | 2019-01-15 | Zafgen Inc | Métodos de tratamiento de enfermedad renal y otros trastornos. |
| CN106432255A (zh) | 2015-08-11 | 2017-02-22 | 扎夫根公司 | 烟曲霉素醇螺环化合物和制备和使用其的方法 |
| AR105671A1 (es) | 2015-08-11 | 2017-10-25 | Zafgen Inc | Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso |
| CN106591389B (zh) * | 2015-10-15 | 2019-10-11 | 中国科学院微生物研究所 | 一种利用烟曲霉菌生产烟曲霉素的方法 |
| CN105622593B (zh) * | 2016-02-25 | 2018-06-26 | 中国农业科学院蜜蜂研究所 | 一种烟曲霉素的提取方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2791530A (en) * | 1953-08-31 | 1957-05-07 | Abbott Lab | Stabilized fumagillin compositions |
| JPH0629278B2 (ja) * | 1985-06-26 | 1994-04-20 | 藤沢薬品工業株式会社 | オキサスピロオクタン化合物 |
| US5135920A (en) * | 1988-11-16 | 1992-08-04 | Takeda Chemical Industries, Ltd. | Angiostatic agents |
| JPH06504262A (ja) * | 1990-07-27 | 1994-05-19 | レブリゲン コーポレーション | 脈管形成性の病気の処置用の新規な方法と組成物 |
| US5328930A (en) * | 1993-03-01 | 1994-07-12 | Emory University | Treatment of microsporidial and acanthamoeba keratoconjunctivitis with topical fumagillin |
| CA2216623C (en) * | 1995-03-27 | 2005-05-31 | Sanofi | Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections |
| EP0799616A1 (en) * | 1996-04-01 | 1997-10-08 | Takeda Chemical Industries, Ltd. | Oral composition comprising a fumagillol derivative |
| CA2210600A1 (en) * | 1996-07-17 | 1998-01-17 | Takashi Houkan | Inhibitor of tumor metastasis or recurrence |
| AU3968597A (en) * | 1996-08-02 | 1998-02-25 | Children's Medical Center Corporation | Method of regulating the female reproductive system through angiogenesis inhibitors |
-
1996
- 1996-03-26 CA CA002216623A patent/CA2216623C/en not_active Expired - Lifetime
- 1996-03-26 CN CN96192923A patent/CN1072485C/zh not_active Expired - Lifetime
- 1996-03-26 EA EA199700267A patent/EA000150B1/ru not_active IP Right Cessation
- 1996-03-26 TR TR97/01048T patent/TR199701048T1/xx unknown
- 1996-03-26 PL PL96322470A patent/PL183378B1/pl unknown
- 1996-03-26 HU HU9801220A patent/HU224028B1/hu active IP Right Grant
- 1996-03-26 DE DE69600879T patent/DE69600879T2/de not_active Expired - Lifetime
- 1996-03-26 CZ CZ19973049A patent/CZ286821B6/cs not_active IP Right Cessation
- 1996-03-26 JP JP52900196A patent/JP3260378B2/ja not_active Expired - Lifetime
- 1996-03-26 AT AT96909200T patent/ATE172641T1/de active
- 1996-03-26 ES ES96909200T patent/ES2128846T3/es not_active Expired - Lifetime
- 1996-03-26 AP APAP/P/1997/001092A patent/AP646A/en active
- 1996-03-26 EP EP96909200A patent/EP0817626B1/fr not_active Expired - Lifetime
- 1996-03-26 DK DK96909200T patent/DK0817626T3/da active
- 1996-03-26 KR KR1019970706675A patent/KR100286920B1/ko not_active Expired - Lifetime
- 1996-03-26 AU AU52786/96A patent/AU706161B2/en not_active Expired
- 1996-03-26 NZ NZ304906A patent/NZ304906A/xx not_active IP Right Cessation
- 1996-03-26 US US08/913,360 patent/US5900431A/en not_active Expired - Lifetime
- 1996-03-26 UA UA97094765A patent/UA41446C2/uk unknown
- 1996-03-26 WO PCT/FR1996/000448 patent/WO1996030010A2/fr not_active Ceased
- 1996-03-26 SK SK1307-97A patent/SK283883B6/sk not_active IP Right Cessation
-
1997
- 1997-09-11 IS IS4557A patent/IS2048B/is unknown
- 1997-09-26 NO NO19974466A patent/NO315968B1/no not_active IP Right Cessation
- 1997-09-26 OA OA70088A patent/OA10515A/fr unknown
-
2006
- 2006-04-04 FR FR06C0014C patent/FR06C0014I2/fr active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HU224028B1 (hu) | Fumagillol és származékai alkalmazása bélfertőzések kezelésére szolgáló gyógyszerek előállítására | |
| JP5441287B2 (ja) | 心血管事象を予防するための必須脂肪酸 | |
| DE69109286T2 (de) | Pharmazeutische zusammensetzung. | |
| EP0264187B1 (en) | Pharmaceutical composition containing ibuprofen and aluminium hydroxide | |
| US4446140A (en) | Method and composition for treating mouth pain | |
| WO2000037078A1 (de) | Kombination von cerivastatin und fibraten | |
| JPH05186332A (ja) | 少なくとも２種の異なる作用物質を備えた薬剤学的製剤の製造方法と使用 | |
| US5264222A (en) | Oral pharmaceutical compositions in unit dosage form | |
| JPH1036269A (ja) | 月経困難症及び／又は月経前症候群の軽減用薬剤 | |
| EP1408977B1 (en) | A combination therapy for the treatment of heart failure | |
| EP0190851B1 (en) | Improved antiinflammatory composition | |
| MXPA97007150A (en) | Use of fumagilol and its derivatives to prepare medicines intended to combat intestine infections | |
| JP4233766B2 (ja) | 高い薬用量でのジエノゲストの使用 | |
| JPS61134315A (ja) | 解熱鎮痛剤 | |
| JPH0132804B2 (enExample) | ||
| WO2020242410A1 (en) | Pharmaceutical compositions comprising ursodeoxycholic acid as active substance | |
| JPS58210010A (ja) | 抗腫瘍剤 | |
| WO2009071405A1 (en) | Megestrol acetate for reducing the mortality and/or improving quality of life in cancer patients | |
| MXPA01008213A (en) | Essential fatty acids in the prevention of cardiovascular events |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HFG4 | Patent granted, date of granting |
Effective date: 20050322 |